Comparative study of the toxicity of 5-fluorouracil-adriamycin- cyclophosphamide versus adriamycin-cyclophosphamide followed by paclitaxel in carcinoma breast

Indian Journal of Cancer

Volumn 48, Issue 1, 2011, Pages 68-73

  Palappallil, Dhanya S ^a   Nair, Bindu Latha R ^b   Jayakumar, K L ^b   Puvathalil, Ramani T ^b  

^a Government Medical College   (India)

^b GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

Adriamycin Cyclophosphamide; breast carcinoma; Fluorouracil Adriamycin Cyclophosphamide; toxicity

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; GRANISETRON; PACLITAXEL; PHENIRAMINE MALEATE; RANITIDINE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BRADYCARDIA; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RISK; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DYSPNEA; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERPIGMENTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL; NAUSEA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY; PRACTICE GUIDELINE; PROSPECTIVE STUDY; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79951987032     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.75836     Document Type: Article

References (11)

1. Sinha R, Anderson DE, McDonald SS, Greenwald P. Cancer risk and diet in India. J Postgrad Med 2003;49:222-8. (Pubitemid 37493414)
2. Adjuvant Therapy for Breast Cancer. NIH Consensus Statement Online 2000;17:1-23.
3. National Cancer Institution-NCI Toxicity Criteria formatted. Available from: http://www.download.bham.ac.uk/bctu/AML16/Trial/DocsForExistingCentres/ National%20Cancer%20Institution-NCI%20Toxicity%20Criteria%20formatted.pdf.
4. Schag CC, Heinrich RL, Ganz PA. Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol 1984;2:187-93. (Pubitemid 14138407)
5. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83. (Pubitemid 46594124)
6. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node- positive breast cancer. N Engl J Med 2005;352:2302-13. (Pubitemid 40740554)
7. Kuraparthy S, Reddy KM, Yadagiri LA, Yutla M, Venkata PB, Kadainti SV, et al. Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India. World J Surg Oncol 2007;5:56.
8. Abu-Khalaf MM, Windsor S, Ebisu K, Salikooti S, Ananthanarayanan G, Chung GG, et al. Five-year update of an expanded phase II study of dose-dense and intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer. Oncology 2005;69:372-83. (Pubitemid 41797913)
9. Buzdar AU, Blumenschein GR, Gutterman JU, Tashima CK, Hortobagyi GN, Smith TL, et al. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide and BCG vaccine: A follow up report. JAMA 1979;242:1509-13. (Pubitemid 10243608)
10. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node- positive carcinoma breast. N Engl J Med 1994;330:1253-9.
11. Burtness B, Windsor S, Holston B, DiStasio S, Staugaard-Hahn C, Abrantes J, et al. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting. Cancer J Sci Am 1999;5:224-9. (Pubitemid 29528750)